B.R.A.H.M.S.(Brahms)

What B.R.A.H.M.S.(Brahms) does

B.R.A.H.M.S. GmbH is a German in vitro diagnostics developer and manufacturer, founded in 1994 and headquartered in Hennigsdorf, operating as a wholly-owned subsidiary of Thermo Fisher Scientific. The company specializes in clinical biomarker assay development and the production of KRYPTOR automated random-access benchtop immunoanalyzers, which run on TRACE (Time-Resolved Amplified Cryptate Emission) technology — a Nobel Prize-winning homogeneous immunoassay platform licensed from Cisbio Bioassays. Its assay portfolio spans five clinical verticals: prenatal screening (PAPP-A, Free βhCG, AFP, PlGF, hCG+β, uE3, Inhibin A, and the FDA-approved sFlt-1/PlGF preeclampsia test), oncology (FDA-cleared CgA II for neuroendocrine tumor monitoring), endocrinology (thyroid markers including TRAK human), acute care (Copeptin proAVP for AMI rule-out), and infectiology (PCT/Procalcitonin for sepsis and antibiotic stewardship, plus MR-proADM).

The business operates a hardware-plus-consumables razor-and-blade model: KRYPTOR analyzers are sold to clinical laboratories, generating recurring revenue through proprietary B.R.A.H.M.S. biomarker assay reagents. Products are distributed exclusively through Thermo Fisher Scientific's global enterprise sales force and worldwide distribution network, reaching clinical laboratories and healthcare facilities across multiple geographies. Pricing is quote-based enterprise sales rather than list-priced, consistent with capital equipment procurement in regulated clinical settings. The company holds approximately 100 patent families across its biomarker portfolio and maintains IVDR compliance in the EU while pursuing FDA clearances in the US, where it secured two first-mover approvals in 2024. Control and strategic direction flow from Thermo Fisher Scientific's corporate leadership, with B.R.A.H.M.S. functioning as an integrated brand within Thermo Fisher's Clinical & Diagnostics portfolio.

Name

B.R.A.H.M.S.(Brahms)

Legal name

B·R·A·H·M·S GmbH

Website

https://brahms.de

Company type

Private

Founded year

1994

Operating status

Operating

Headcount range

501–1,000 employees

Short description

B·R·A·H·M·S is a German in vitro diagnostics subsidiary of Thermo Fisher Scientific that develops and manufactures proprietary biomarker assays and KRYPTOR automated immunoanalyzers, serving clinical laboratories across prenatal screening, oncology, endocrinology, acute care, and infectiology applications globally.

Ownership category

akta.pro rank

Product category

Clinical Diagnostics / In Vitro Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB)

Keywords

• In vitro diagnostics
• Biomarker assays
• Immunoanalyzer instruments
• Prenatal screening tests
• Clinical diagnostic reagents

Headquarters

HQ city

Hennigsdorf

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales

Revenue model

1. KRYPTOR Analyzers: Sale of KRYPTOR automated immunoanalyzer instruments to clinical laboratories. These are benchtop immunoanalyzers that run B.R.A.H.M.S. biomarker assays.
2. Biomarker Assays and Reagents: Sale of proprietary biomarker assay reagents and consumables including PCT, Copeptin, MR-proADM, prenatal screening markers, thyroid markers, and tumor markers (CgA II) that run on KRYPTOR analyzers.
3. Service and Support: Technical support, service, and maintenance for KRYPTOR analyzers and B.R.A.H.M.S. product portfolio.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

B·R·A·H·M·S develops, manufactures and sells in vitro diagnostic biomarker assay kits and the KRYPTOR line of fully automated benchtop immunoanalyzer instruments for clinical laboratories. Its test menu spans prenatal screening (PAPP-A, Free βhCG, AFP, PlGF, hCG+β, uE3, Inhibin A, sFlt-1/PlGF), oncology (CgA II), endocrinology/thyroid markers (TRAK human), acute care (Copeptin proAVP) and infectiology (PCT/Procalcitonin, MR-proADM). All assays run on KRYPTOR analyzers powered by licensed TRACE homogeneous immunoassay technology.

Product overview

B·R·A·H·M·S is a biomarker diagnostics portfolio under Thermo Fisher Scientific offering a unified system of immunoanalyzers and biomarker assays. The core product ecosystem centers on B·R·A·H·M·S KRYPTOR Analyzers (fully automated random-access benchtop immunoanalyzers using Nobel Prize winning TRACE technology) combined with an extensive test menu of biomarker assays spanning prenatal screening (PAPP-A, Free βhCG, AFP, PlGF, hCG+β, uE3, Inhibin A, sFlt-1/PlGF), oncology (CgA II KRYPTOR), endocrinology/thyroid markers (TRAK human), acute care (Copeptin proAVP), and infectiology (PCT/Procalcitonin, MR-proADM). The portfolio also includes B·R·A·H·M·S Fast Screen Software for data analysis. This analyzer-plus-assay model enables clinical laboratories to perform precise and reliable diagnostic testing across multiple clinical areas using a single automated platform.

Differentiator

Problem solved

Functional benefit

Brands

• KRYPTOR Analyzers: Fully automated random-access benchtop immunoanalyzers that use TRACE technology for diagnostic testing in clinical laboratories. Models include KRYPTOR compact PLUS.
• B·R·A·H·M·S Prenatal Screening Solutions
• B·R·A·H·M·S Thyroid Markers
• B·R·A·H·M·S CgA II KRYPTOR
• B·R·A·H·M·S Copeptin proAVP KRYPTOR
• B·R·A·H·M·S PCT (Procalcitonin)
• B·R·A·H·M·S MR-proADM
• TRACE Technology

Products and services

• B·R·A·H·M·S KRYPTOR Analyzers Fully automated random-access benchtop immunoanalyzers that use Nobel Prize winning TRACE technology to deliver fast and reliable test results for prenatal screening, oncology, endocrinology, infectiology and acute care testing in clinical laboratories.
• B·R·A·H·M·S CgA II KRYPTOR First FDA-cleared automated immunofluorescent assay for fast, precise and efficient monitoring of neuroendocrine tumors in conjunction with other clinical methods. Chromogranin A is considered the gold standard for therapy monitoring in neuroendocrine cancers.
• B·R·A·H·M·S Copeptin proAVP KRYPTOR Assay Reliable surrogate marker assay of vasopressin (AVP/ADH) used for ruling out acute myocardial infarction (AMI) when combined with troponin and for differential diagnosis of polyuria-polydipsia syndrome. Smaller sample volumes, fast time to results and proven preanalytical stability.
• B·R·A·H·M·S sFlt-1/PlGF KRYPTOR Test System First FDA-approved test system for risk assessment of preeclampsia with severe features, used for preeclampsia management and risk stratification in pregnancy.
• B·R·A·H·M·S Prenatal Screening Assays Comprehensive biomarker assays for first and second trimester prenatal screening, including PAPP-A KRYPTOR, Free βhCG KRYPTOR, PlGF plus KRYPTOR, AFP KRYPTOR, hCG+β KRYPTOR, uE3 KRYPTOR and Inhibin A KRYPTOR, covering fetal aneuploidies and neural tube defects.
• B·R·A·H·M·S Thyroid Markers Biomarker assays for thyroid disease diagnosis and monitoring, including markers for thyroid cancer, Graves' disease and Hashimoto's thyroiditis, including the B·R·A·H·M·S TRAK human KRYPTOR Assay.
• B·R·A·H·M·S MR-proADM Biomarker assay for infectiology used in sepsis diagnosis and management, and for assessing patients with infectious diseases.
• B·R·A·H·M·S PCT (Procalcitonin) Essential biomarker tool for combating antibiotic overuse and resistance, used for antibiotic stewardship and sepsis management in infectiology on KRYPTOR analyzers.

Quantifiable outcome

• Birth defects affect approximately 6% of babies worldwide; preeclampsia affects 2-4% of all pregnancies
• +1 more outcomes

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Cisbio BioassayscoreTechnology or IntegrationKRYPTOR and TRACE technology are trademarks of Cisbio Bioassays, licensed for exclusive use by B.R.A.H.M.S GmbH, a part of Thermo Fisher Scientific. This licensing agreement provides B.R.A.H.M.S access to Nobel Prize winning TRACE technology for their KRYPTOR immunoanalyzer systems used in clinical biomarker diagnostics.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Hologic: Diagnostics division (Pancheck, Aptima) operates specialty assays in women's health and oncology — partially overlapping with B·R·A·H·M·S's prenatal screening and neuroendocrine tumor monitoring indications.
• Meso Scale Diagnostics: Specialty multiplex immunoassay platform serving biomarker discovery, translational research, and clinical sample analysis — overlaps with B·R·A·H·M·S in the immunoassay/biomarker detection space with a research-grade focus.

Direct peers

• DiaSorin: Specialty immunoassay company with LIAISON platform serving clinical labs in infectious disease, endocrinology, and oncology — closely comparable to B·R·A·H·M·S in scale, menu focus, and target customer.
• bioMérieux: Specialty IVD company whose VIDAS immunoassay platform runs a comparable menu of biomarkers (PCT, cardiac, infectious disease) — a focused, specialty-driven competitor with similar hospital lab customer profile.

Broad incumbents

• Beckman Coulter Diagnostics: Part of Danaher; Access/DxI immunoassay platforms compete in hospital core labs across broad menus including cardiac, thyroid, reproductive, and infectious disease markers.
• Siemens Healthineers: Operates ADVIA Centaur and Atellica immunoassay platforms with broad menu overlap including cardiac, sepsis, thyroid, and reproductive endocrinology markers competing with B·R·A·H·M·S assays.
• Roche Diagnostics: Largest in vitro diagnostics company globally; operates cobas immunoassay analyzer platforms that compete directly with KRYPTOR in clinical laboratories across the same biomarker menu (cardiac, sepsis, prenatal, thyroid).
• Abbott Diagnostics: Major IVD player with Architect and Alinity immunoassay platforms serving clinical labs in cardiology, infectious disease, oncology, and prenatal screening — directly competing with B·R·A·H·M·S's menu.
• QuidelOrtho: Diagnostics company offering immunoassay and specialty testing (including Sofia, Triage, Vitros) — overlapping in hospital/clinical lab channels with biomarker menu in cardiac and infectious disease.

Others

• Revvity (formerly PerkinElmer): Parent of Cisbio Bioassays — the licensor of B·R·A·H·M·S's core TRACE/KRYPTOR technology. Strategic counterpart as the IP licensor and a participant in immunoassay/diagnostic reagents.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/brahms-aktiengesellschaft

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about B.R.A.H.M.S.(Brahms)